Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Takeda Pharmaceutical (TKPHF) Income from Continuing Operations (2017 - 2025)

Historic Income from Continuing Operations for Takeda Pharmaceutical (TKPHF) over the last 9 years, with Q4 2025 value amounting to $1.1 billion.

  • Takeda Pharmaceutical's Income from Continuing Operations fell 1937.44% to $1.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $14.0 billion, marking a year-over-year increase of 3346.36%. This contributed to the annual value of $709.9 million for FY2025, which is 2899.72% down from last year.
  • Takeda Pharmaceutical's Income from Continuing Operations amounted to $1.1 billion in Q4 2025, which was down 1937.44% from $7.5 billion recorded in Q3 2025.
  • Over the past 5 years, Takeda Pharmaceutical's Income from Continuing Operations peaked at $7.5 billion during Q3 2025, and registered a low of $487.8 million during Q3 2022.
  • Its 5-year average for Income from Continuing Operations is $2.1 billion, with a median of $1.4 billion in 2024.
  • In the last 5 years, Takeda Pharmaceutical's Income from Continuing Operations skyrocketed by 64822.38% in 2021 and then tumbled by 7115.93% in 2022.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Income from Continuing Operations stood at $761.5 million in 2021, then fell by 11.55% to $673.6 million in 2022, then surged by 161.65% to $1.8 billion in 2023, then dropped by 25.02% to $1.3 billion in 2024, then dropped by 19.37% to $1.1 billion in 2025.
  • Its Income from Continuing Operations was $1.1 billion in Q4 2025, compared to $7.5 billion in Q3 2025 and $2.6 billion in Q2 2025.